You can buy or sell PCRX and other stocks, options, ETFs, and crypto commission-free!
Pacira Pharmaceuticals, Inc. operates as a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. Read More The company was founded in December 2006 and is headquartered in Parsippany, NJ.
Parsippany, New Jersey
52 Week High
52 Week Low
Pacira Pharmaceuticals Inc.
Shares of Pacira Pharmaceuticals Inc. fell 1.9% in premarket trade Tuesday after the company announced it was planning to acquire MyoScience Inc., a privately-held company that markets an FDA-approved non-opioid treatment for pain associated with osteoarthritis and knee replacement surgery. MyoScience's therapy, called Iovera, is a device that delivers doses of cold temperature to targeted nerves, which temporarily stops those nerves from sending pain signals -- a technique known as cryoanalgesia. Pacira th...
Seeking AlphaFeb 28
Pacira Pharmaceuticals beats by $0.20, beats on revenue
Pacira Pharmaceuticals (NASDAQ:PCRX): Q4 Non-GAAP EPS of $0.47 beats by $0.20; GAAP EPS of $0.20 beats by $0.14. Revenue of $95.12M (+20.3% Y/Y) beats by $1.41M . Press Release...
Expected May 2, Pre-Market